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Abs t r a c t Human Gb3 /CD77 syn t h a s e (α1 , 4 -
galactosyltransferase) is the only known glycosyltransferase
that changes acceptor specificity because of a point mutation.
The enzyme, encoded by A4GALT locus, is responsible for
biosynthesis of Gal(α1–4)Gal moiety in Gb3 (CD77, Pk anti-
gen) and P1 glycosphingolipids. We showed before that a
single nucleotide substitution c.631C > G in the open reading
frame of A4GALT, resulting in replacement of glutamine with
glutamic acid at position 211 (substitution p. Q211E),
broadens the enzyme acceptor specificity, so it can not only
attach galactose to another galactose but also to N-
acetylgalactosamine. The latter reaction leads to synthesis of
NOR antigens, which are glycosphingolipids with terminal
Gal(α1–4)GalNAc sequence, never before described in mam-
mals. Because of the apparent importance of position 211 for
enzyme activity, we stably transfected the 2102Ep cells with
vectors encoding Gb3/CD77 synthase with glutamine
substituted by aspartic acid or asparagine, and evaluated the
cells by quantitative flow cytometry, high-performance thin-
layer chromatography and real-time PCR. We found that cells
transfected with vectors encoding Gb3/CD77 synthase with
substitutions p. Q211D or p. Q211N did not express Pk, P1
and NOR antigens, suggesting complete loss of enzymatic
activity. Thus, amino acid residue at position 211 of Gb3/
CD77 synthase is critical for specificity and activity of the
enzyme involved in formation of Pk, P1 and NOR antigens.
Altogether, this approach affords a new insight into the mech-
anism of action of the human Gb3/CD77 synthase.
Keywords Gb3/CD77 synthase . P1PK blood group system .
NOR polyagglutination . Glycopshingolipids . Site-directed
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Introduction
Glycosyltransferases are a large group of enzymes that syn-
thesize carbohydrate moieties of glycoproteins, glycosamino-
glycans and glycosphingolipids. These molecules are in-
volved in many processes, such as cell differentiation, signal
transduction, immune response and pathogen infection [1].
They also contribute to diversity of many human blood group
antigens belonging to blood group systems such as ABO,
Lewis or P1PK [2, 3]. The reactions catalyzed by glycosyl-
transferases involve transferring sugar residues from the sugar
donors to the acceptor molecules, forming glycosidic bonds.
Donor sugar substrates are usually activated in the form of
nucleoside diphosphate sugars (e.g. UDP-Gal) or nucleoside
monophosphate sugars (e.g. CMP-NeuNAc). The acceptor
substrates can be sugars, lipids, proteins or small molecules
such as coumarin [1, 4]. Many glycosyltransferases (nearly all
belonging to the GTA superfamily) require divalent metal ion
(usually manganese) at the catalytic center, where it is
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coordinated by twoD residues that form the DXDmotif [4]. In
general, glycosyltransferases reveal high donor and acceptor
specificity, and it was demonstrated that mutations in genes
encoding glycosyltransferases may lead to changes in either
[5]. However, while change in donor specificity is a well
described phenomenon and has been shown for several
enzymes, such as ABO transferase [6] or β1,4-
galactosyltransferase [7], the change of acceptor speci-
ficity has been demonstrated for only one enzyme, Gb3/
CD77 synthase, which is a glycosphingolipid-specific
glycosyltransferase [8].
Glycosphingolipids are amphipathic compounds
consisting of hydrophilic carbohydrate and hydrophobic cer-
amide moieties [9]. Glycosphingolipids constitute a signifi-
cant portion of mammalian cell membranes, including intra-
cellular compartments. In humans, four major types of
glycosphingolipid neutral root structures (called series) can
be distinguished: the globo (GalNAcβ1-3Galα1-4Galβ1-
4Glc), lacto (Galβ1-3GlcNAcβ1-3Galβ1-4Glc), neolacto
(Galβ1-4GlcNAcβ1-3Galβ1-4Glc) and ganglio (Galβ1-
3GalNAcβ1-4Galβ1-4Glc) [10, 11]. In addi t ion,
glycosphingolipids of all series may contain sialic acid
and these are traditionally (albeit confusingly) called gan-
gliosides or acidic glycosphingolipids; most of them have
ganglio or neolacto core chains. Glycosphingolipids on
blood and tissue cells may carry histo-blood group anti-
gens, such as A, B, Pk or P1 [3].
Gb3/CD77 synthase (UDP-Gal:lactosylceramide α1,4-
galactosyltransferase; α1,4-galactosyltransferase), encoded
by A4GALT gene, catalyzes the transfer of galactose from
UDP-galactose to lactosylceramide (LacCer), giving rise to
g l o bo - s e r i e s p a t hway. Th e p r o du c t i s c a l l e d
globotriaosylceramide (Gb3), CD77 or Pk blood group anti-
gen [12]. P1 antigen is synthesized further downstream from
lactosylceramide in the neolacto-series pathway, which is a
separate entity. Paragloboside, the precursor for P1 antigen,
serves also as a precursor for human histo-blood group H, A
and B antigens (Fig. 1). Recently, we have shown that Gb3/
CD77 synthase is responsible for synthesis of P1 blood group
antigen [13]. Both Pk and P1 antigens are terminated with
Gal(α1–4)Gal moiety. Pk antigen can be elongated by β1,3-
N-acetylgalactosaminyltransferase (P synthase) giving rise to
globoside (P antigen, Gb4), which is the most abundant neu-
tral glycosphingolipid on erythrocytes [14]. The same enzyme
synthesizes PX2 glycosphingolipid from paragloboside [15]
(Fig. 1). Both antigens are now classified as members of the
GLOB blood group system [16]. The Forssman antigen,
very rare in humans but present in several mammalian
species, is synthesized when a single point mutation is
present in GBGT1 (otherwise a pseudogene in humans)
encoding α1,3-N-acetylgalactosaminyltransferase [17].
The Forssman antigen is now classified as a sole member
of the FORS blood group system [16].
Both Pk and P1 antigens belong to the P1PK blood
group system, and the presence or absence of P1 antigen
on erythrocytes determines the P1 (P1-positive) or P2 (P1-
negative) blood group, respectively [3]. The null pheno-
type caused by mutation in A4GALT gene, is called p [3].
Despite several attempts, the molecular background of the
P1PK blood group system is still not fully elucidated.
Several authors have shown that the expression levels of
A4GALT mRNA is higher in P1 than in P2, and there is a
general agreement that the upregulated transcript may
cause increased production of Gb3/CD77 synthase
[18–20]. However, despite finding several SNPs associat-
ed with P1/P2 status, no credible mechanism for allelic
variation in A4GALT gene expression has been proposed.
The NOR antigen, fully elucidated in our laboratory, is
an unusual glycosphingolipid with terminal Gal(α1–
4)GalNAc moiety, found in erythrocytes of individuals
with the rare NOR polyagglutination syndrome [21]. The
erythrocytes of NOR-positive individuals contain unique





3)Gal(α1–4)Gal(β1–4)GlcCer [22]. We demonstrated that
a single point mutation c.631C > G in A4GALT resulting
in replacement of glutamine with glutamic acid at position
211 (substitution p. Q211E) broadens the acceptor speci-
ficity of the Gb3/CD77 synthase; as a result, the variant
enzyme is able to catalyze the synthesis of two different
terminal disaccharide moieties: Gal(α1–4)Gal (in Pk and
P1 antigens) and Gal(α1–4)GalNAc (in NOR antigens)
[8] (Fig. 1). The NOR antigen has been classified as the
third member of the P1PK blood group system [16]. The
NOR phenotype is rare, but its biological role is signifi-
cant, because natural anti-NOR antibodies present in hu-
man sera recognize the terminal trisaccharide unit
(Gal(α1–4)GalNAc(β1–3)Gal) of NOR1 and NOR2
glycosphingolipids [23]. The presence of these antibodies,
common in general population, underlies a rare phenom-
enon known as inheritable NOR polyagglutination: red
blood cells of NOR-positive individuals are agglutinated
by most human sera, which disqualifies such individuals
as blood donors [24].
Gb3/CD77 synthase is the first described enzyme in
which a single amino acid substitution leads to the
change of acceptor specificity, and this finding suggests
that amino acid residue 2011 determines the catalytic
properties of the Gb3/CD77 synthase. Here we use site-
directed mutagenesis combined with quantitative analysis
of glycosphingolipid antigens expression to evaluate the
role of amino acid residue 211 in the specificity and
activity of the enzyme.
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Materials and methods
Site-directed mutagenesis
Site-directed mutagenesis was performed using overlap-
extension PCR, as described previously [8]. In the first
PCR reaction, two fragments of A4GALT were created,
each containing the overlapping site with introduced mu-
tation. In the second reaction, the PCR products were
duplexed to generate new template DNA. During the
overlap extension phase, each fused product was ampli-
fied using primers complementary to the pCAG vector
(pCAGsense and pCAGanti). The resulting full-length
gene fragments were directly ligated into the pGEM-T
Easy Vector and then digested with XhoI and NotI
(Fermentas, Vilnius, Lithuania), cloned into appropriately
digested pCAG vector and confirmed by sequencing
(Genomed, Warsaw, Poland) using primers PkSeqFor
and PkSeqRev. The plasmids were purified using maxi
prep kit (Qiagen, Venlo, Netherlands) according to the
manufacturer’s instruction. The reaction was performed
in a MJ Mini gradient PCR apparatus (BioRad,
Hercules, CA, USA). 20 μl reaction mixture contained:
amount of DNA solution containing approximately
200 ng of the template, 0.2 mM forward and reverse
primers, 0.2 mM dNTPs, 1.5 mM MgCl2, HF polymerase
buffer (1:10 dilution), 1 unit Phusion High-Fidelity DNA
Polymerase (Fermentas, Vilnius, Lithuania). The DNA
fragments were purified with gel extraction kit (Gel-Out,
A&A Biotechnology, Gdynia, Poland). The sequences of
primers are shown in Table 1, and the conditions of PCR
reactions are shown in Table 2.
Cell culture and transfection
The teratocarcinoma cell line 2102Ep was a generous gift
from Dr. Peter W. Andrews (University of Sheffield, UK)
[25]. The cells were grown in Dulbecco’s Modified Eagle
Medium (DMEM) containing 4.5 g/l glucose (Invitrogen,
Carlsbad, CA, USA), 10 % fetal calf serum (Invitrogen,
Carlsbad, CA, USA), and 2 mM GlutaMAX (Invitrogen,
Carlsbad, CA, USA) under a humidified atmosphere of 5 %
CO2 and at 37 °C. Culture mediumwas changed every second
or third day, and after reaching 85–90 % confluence, the cells
were passaged using 0.25 % trypsin/1 mM EDTA.
The cells were seeded at 2 × 105 cells per well in six-well
plates the day before transfection, so that confluence at day of
transfection was about 60 %. 3 h before transfection the me-
dium was replaced with fresh DMEM. The cells were
transfected using 10 μg polyethylenimine (Polysciences,
Warrington, PA, USA). Plasmid DNA in an amount of 3 μg
Fig. 1 Schematic representation of biosynthesis of ABO, P1PK, GLOB and FORS blood group antigens
Table 1 Nucleotide sequences of primers used in site-directed
mutagenesis and sequencing
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was diluted in 200 μl 0.15 M NaCl and then mixed briefly
with polyethylenimine. The transfection mixture was incubat-
ed for 20 min at room temperature and then added dropwise to
each well. The next day (after 18–20 h) medium was replaced
with fresh DMEM. 48 h after transfection, cells were subject-
ed to puromycin selection (Sigma-Aldrich, St. Louis, MO,
USA) at a concentration of 0.44 μg/ml. The medium with
antibiotic was changed daily for 10 days and then every 2 days.
Selection was carried out until the non-transfected control
cells were dead.
Antibodies
The mouse monoclonal anti-NOR antibody, nor118 was ob-
tained in our laboratory before and used as a diluted culture
supernatant [24]. Antibodies: human anti-P1, mouse anti-P1,
goat anti-mouse IgM conjugated with fluorescein isothiocya-
nate (FITC), and goat anti-mouse IgG conjugated with FITC
antibodies were purchased from Immucor Inc. (Norcross, GA,
USA), CE-Immundiagnostika (Eschelbronn, Germany), Santa
Cruz Biotechnology (Dallas, TX, USA) and Dako (Glostrup,
Denmark), respectively. The goat anti-human IgM conjugated
with FITC antibodies was purchased from Pierce (Rockford,
IL, USA), and biotinylated anti-mouse antibody and biotinyl-
ated anti-human antibody were purchased from Sigma-
Aldrich (St. Louis, MO, USA).
Flow cytometry
The cells were incubated with 100 μl appropriately diluted
primary antibodies (human anti-P1 1:10, mouse anti-P1
1:10, anti-NOR 1:20) for 60 min on ice. Then the cells were
washed (all washes and dilutions were done with PBS) and
incubated with 100 μl (diluted 1:50) FITC-labeled anti-mouse
IgM antibody for 40 min on ice in the dark. The cells were
washed and approximately 5 × 105 cells were suspended in
750 μl of cold PBS and analyzed by flow cytometry using
FACSCalibur (BD Biosciences, Franklin Lakes, NJ, USA).
The number of events analyzed was 10,000/gated cell popu-
lation. The analysis of the results was carried out using Flow
Jo software (Tree Star, Ashland, OR, USA).
Flow cytometric quantification of cell surface receptor
expression
The cells were prepared as described in the Flow
Cytometry section. The QIFIKIT (Dako, Glostrup,
Denmark) bead populations with defined quantities of an-
tibody molecules attached per a single bead were incubat-
ed with FITC-labeled secondary antibody (goat anti-
mouse IgG conjugated with FITC included in the
QIFIKIT or goat anti-mouse IgM, in which case the anti-
body binding capacities were corrected for differences in
fluorophore to protein ratios). The calibration beads were
then analyzed by flow cytometry and the data were used
for plotting the calibration curves (mean fluorescence in-
tensity versus antibody binding capacity). The cells were
then analyzed by flow cytometry and the antigen density
was calculated by interpolation from the calibration curve
as described in the manufacturer’s protocol. The cells
stained with the respective control were analyzed using
the same protocol.
Extraction and purification of glycosphingolipids
The isolation and fractionation of glycosphingolipids and
the orcinol staining were performed as described previ-
ously [22] . Cel lu lar l ip ids were extracted with
chloroform/methanol from 107 2102Ep cells. The neutral
glycosphingolipids were separated from the phospholipids
and gangliosides, purified in peracetylated form, de-O-
acetylated, and desalted. Glycosphingolipid samples were
solubilized in chloroform/methanol (2:1, v/v), applied to
HPTLC plates (Kieselgel 60, Merck, Darmstadt,
Germany), and developed with chloroform/methanol/wa-
ter (55:45:9, v/v/v). The dried plates were immersed in
0.05 % polyisobutylmethacrylate (Aldrich, Steinheim,
Germany) in hexane for 1 min, dried, sprayed with TBS
(0.05 M Tris buffer, 0.15 M NaCl (pH 7.4)), and blocked
in 5 % BSA. For antibody assays, the plates were succes-
sively overlaid with 1) primary antibody diluted in TBS/
1 % BSA (TBS-BSA) for 1–1.5 h; 2) biotinylated goat
anti-mouse Ig antibody (Dako, Glostrup, Denmark), dilut-
ed 1:5000 with TBS-BSA; 3) ExtrAvidin-alkaline phos-
phatase conjugate (Sigma-Aldrich, St. Louis, MO, USA)
Table 2 PCR conditions used in
site-directed mutagenesis Mutagenesis – first step Mutagenesis – second step
temp [°C] time [s] cycle temp [°C] time [s] cycle
Initial denaturation 94 180 1 94 180 1
Denaturation 94 30 30 94 30 30
Annealing 65–75 30 30 65–75 30 30
Extension 72 75 30 72 100 30
Final extension 72 600 1 72 600 1
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diluted 1:1000 with TBS/ BSA/0.2 % Tween20 for 1 h;
and 4) the substrate solution (nitro blue tetrazolium/5-bro-
mo-4-chloro-3-indolyl phosphate, Sigma-Aldrich). Other
details were as described previously [22, 26]. Each
HPTLC experiment was repeated three times.
Quantitative analysis of transcripts
Total RNA from different 2102Ep clones was prepared using
RNeasy mini kit (Qiagen, Venlo, Netherlands) and the com-
plementary DNAs (cDNAs) were synthesized using
SuperScript III First-Strand Synthesis kit (Life Technologies,
Carlsbad, CA, USA) with oligo(dT) primers. Quantitative po-
lymerase chain reaction (qPCR) was performed on 30 ng of
cDNA using the 7500 Fast Real-Time PCR System (Life
Technologies), according to the manufacturer’s instruction.
The RNA samples not treated with reverse transcriptase
(RT-) were also evaluated to check for genomic DNA contam-
ination. The A4GALT transcripts were detected with Custom
TaqMan Gene Expression Assay. The ORF sequences were
chosen in assay design to enable detection of transcripts orig-
inating from plasmids. A predesigned TaqMan assay targeting
exon 2–3 boundary (Hs00213726_m1; Life Technologies)
was also used to ensure equal amount of the endogenous
A4GALT transcript in untransfected and transfected cells.
The transcript quantities were normalized to ACTB (β-actin)
endogenous control (assay Hs99999903_m1). All samples
were run in triplicates. The untransfected cells sample (NAT)
was used as the calibrator. Data were analyzed using Sequence
Detection software Version 1.3.1 (Life Technologies). Target
nucleotide sequences are shown in Table 3, while real-time
PCR conditions are in Table 4.
Results
We showed before that c.631C > G mutation in A4GALT
resulting in substitution of glutamine with glutamic acid at
position 211 (substitution p. Q211E) of the Gb3/CD77 syn-
thase is responsible for synthesis of NOR antigen [8]. To ex-
amine how the substitution of 211Q by other amino acid res-
idues influences synthesis of Pk, P1 and NOR antigens, we
stably transfected human teratocarcinoma 2102Ep cells with
pCAG vectors encoding either the consensus Gb3/CD77 syn-
thase or the enzymewith p. Q211N or p. Q211D substitutions.
The results were evaluated by flow cytometry using the fol-
lowing antibodies: anti-NOR, human anti-P1 (which reacts
with P1 antigen only) and mouse anti-P1 (which reacts with
both P1 and Pk antigens). We found that cells transfected with
the vector encoding Gb3/CD77 synthase with substitutions p.
Q211N or p. Q211D did not express Pk, P1 or NOR antigens
(Fig. 2). In contrast, as before, cells transfected with the vector
encoding consensus Gb3/CD77 synthase expressed P1 anti-
gen, and cells transfected with the vector encoding Gb3/CD77
synthase with the previously described p. Q211E substitution
expressed all three antigens: Pk, P1 and NOR.
Neutral glycosphingolipid fractions obtained from the
2102Ep cells transfected with vectors encoding enzymes with
p. Q211D and p. Q211N substitutions were analyzed by thin-
layer chromatography (Fig. 3). The orcinol staining showed
that Gb4Cer is the major neutral glycosphingolipid of NOR-
positive erythrocytes (NOR+); LacCer and Gb3Cer were also
detected, albeit in lower quantity. In contrast, 2102Ep cells
showed different staining profiles, with Gb3Cer being the pre-
dominant species, smaller amounts of Gb4Cer and traces of
LacCer in the case of all Gb3/CD77 variants. Since HPTLC
analysis was done on different occasions, there are three
panels with orcinol staining as standards. We found that hu-
man anti-P1 antibody, which reacts only with P1 antigen, de-
tected P1 antigen in glycosphingolipids from NOR-positive
erythrocytes (NOR+) and from 2102Ep cells transfected with
vectors encoding the consensus Gb3/CD77 synthase (WT)
and p. Q211E Gb3/CD77 synthase (p. Q211E) (Fig. 3a and
c). No bands were visible in fractions obtained from 2102Ep
cells transfected with p. Q211D (p. Q211D) or p. Q211N (p.
Table 3 Target nucleotide sequences within A4GALT open reading
frame used for design of Custom TaqMan Gene Expression Assay
Name of target sequence Sequence (5′→ 3′)
A4gf CTGCACCCT
A4gr TTCTCAAGAAC
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Q211N) enzyme (Fig. 3a and b). The mouse anti-P1 antibody,
which recognizes both Pk and P1 antigens, detected Pk antigen
in glycosphingolipids from erythrocytes, as well as in all frac-
tions from untransfected (NAT) or transfected 2102Ep cells,
while a weak double band (the doublet representing isoforms
differing in length of fatty acid chain in the ceramide moiety)
corresponding to P1 antigen was present only in
glycosphingolipids obtained from erythrocytes and 2102Ep
cells transfected with vectors encoding the consensus enzyme
(WT) and the p. Q211E variant (p. Q211E) (Fig. 3b).
Mouse ant i -NOR ant ibody, which recognizes
glycosphingolipids that terminate with Gal(α1–4)GalNAc
moiety detected two bands in glycosphingolipids from
NOR-positive erythrocytes (NOR+), corresponding to
NOR1 (upper band) and NOR2 (lower band). The antibody
detected a band corresponding to NOR1 only in
glycosphingolipids obtained from cells transfected with the
vector encoding p. Q211E enzyme (p. Q211E) (Fig. 3a). No
band was detected in the neutral glycosphingolipid fraction
obtained from the cells transfected with vectors encoding
Gb3/CD77 p. Q211D synthase (p. Q211D) or Gb3/CD77 p.
Q211N synthase (p. Q211N) (Fig. 3b).
To quantitatively evaluate antigen density on the cells
transfected with vectors encoding various forms of Gb3/
CD77 synthase we used QIFIKIT, which allowed to calculate
the number of antibody molecules bound to cells using flow
cytometry (Fig. 4). Since human anti-P1 antibody is not com-
patible with QIFIKIT (which employs mouse antibodies), we
used mouse anti-P1 antibody to calculate specific antibody
binding capacity on cells transfected with different vectors.
We found that antibody binding capacity of the 2102Ep cells
transfected with the vector encoding the consensus Gb3/CD77
synthase (WT) was smaller (265,601 ± 37,000) in comparison
with the cells harboring the vector encoding the p. Q211E
mutein (p. Q211E) (477,662 ± 67,000), which amounts to
55 % of binding capacity of the 2102Ep cells altered to pro-
duce the p. Q211E variant of the enzyme (Fig. 4a). In contrast,
antibody binding capacity of the cells transfected with vectors
encoding enzyme with p. Q211N (p. Q211N) or p. Q211D (p.
Q211D) substitutions were much lower (1308 ± 176 and
936 ± 208, respectively), thus being close to the antibody
binding capacity of untransfected cells (NAT), which was
573 ± 375. Anti-NOR antibody bound only to the cells
transfected with the vector encoding Gb3/CD77 p. Q211E
synthase (p. Q211E), showing antibody binding capacity of
6902 ± 1966 (Fig. 4b).
Since the expression of Pk, P1 and NOR antigens may be
influenced by the mRNA level, we carried out a quantitative
analysis of A4GALT transcripts in cells transfected with vec-
tors encoding various forms of Gb3/CD77 synthase. The tran-
scripts were markedly upregulated in all transfected cells
(Fig. 5). The differences in endogenous transcript levels be-
tween clones were negligible. Comparison of the samples
treated with reverse transcriptase (RT+) and untreated (RT-)
shows that the differences in relative quantity (RQ) cannot be
attributed to contamination with genomic DNA (Fig. 6).
Discussion
The Gb3/CD77 synthase is an unusual glycosyltransferase,
because it can transfer galactose to two different oligosaccha-
ride acceptors: lactosylceramide and paragloboside, both of
which contain terminal galactose [27]. When E instead of Q
is present at position 211, the enzyme transfers galactose also
to globoside, which contains terminal N-acetylgalactosamine.
This makes the enzyme even more unusual, because glycosyl-
transferase changing acceptor specificity due to a point muta-
tion had not been described until year 2012, when we showed
that suchmutation is the culprit behind NOR antigen synthesis
[8]. Thus, the amino acid residue at position 211 seems to play
an important role in the enzyme specificity. Since relatively
little is known about the mechanism of Gb3/CD77 synthase
action, and the crystal structure has not been solved yet, we
embarked on the site-directed mutagenesis study combined
with quantitative analysis of the expressed antigen. We
substituted the consensus glutamine with either asparagine
or aspartic acid, transfected the 2102Ep cells with vectors
encoding such constructs, established stable clones, and eval-
uated the cells by flow cytometry, high-performance thin-lay-
er chromatography and real-time PCR. Asparagine and
aspartic acid have been selected, because they are structurally
the closest counterparts to glutamine and glutamic acid, re-
spectively, differing by only one methylene group (−CH2-)
in the side-chain (one group in Asn and Asp, versus two
groups in Gln and Glu). We found that cells expressing en-
zymes with D and N at position 211 completely lost the ability
to produce P1 antigen and did not synthesize NOR antigen,
while synthesis of Pk antigen remained at the constitutive lev-
el. However, as described previously, the Gb3/CD77 synthase
with p. Q211E substitution acquired the ability to produce
NOR antigens and at the same time the anti-P1 antibody bind-
ing capacity was markedly decreased in comparison to the
cells transfected with the consensus enzyme. Real-time
PCR analysis showed that the A4GALT mRNA levels in
cells transfected with vectors were about 25–30 times
higher than the levels of mRNA in the untransfected cells
(which were derived only from the endogeneous A4GALT
transcription). In addition, the mRNA level of Gb3/CD77
Fig. 2 Flow cytometry analysis of the binding of human anti-P1, mouse
anti-P1 and anti-NOR antibodies to 2102Ep cells transfected with vectors
encoding various forms of Gb3/CD77 synthase: the consensus Gb3/
CD77 synthase (wild type) containing a Q residue at position 211, Gb3/
CD77 synthase p. Q211E (E at position 211), Gb3/CD77 synthase p.
Q211D (D at position 211), Gb3/CD77 synthase p. Q211N (N at position
211)
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synthase with p. Q211E substitution was 45 % higher than
the level of consensus enzyme mRNA. Since mouse anti-
P1 antibody binding capacity of the cells expressing the
enzyme with p. Q211E substitution was 1.4 times lower
than in the case of cells expressing the consensus enzyme
(WT), it may be speculated that the P1-synthesizing ac-
tivity of the enzyme with substitution of Q by E is about 3
times lower than the activity of the consensus enzyme.
Enzymes with other substitutions (D and N) do not reveal
any activity at all. Thus, p. Q211E substitution causes a
marked decrease of the enzyme activity toward one of its
original acceptors (paragloboside), while conferring activ-
ity toward new acceptor, Gb4Cer, which gives rise to
NOR antigen. Basing on these results, we hypothesize
that activity of Gb3/CD77 synthase depends heavily on
the presence of glutamine (preferred amino acid) or
Fig. 3 HPTLC analysis of neutral glycosphingolipids extracted from
2102Ep cells. The samples of neutral glycosphingolipids obtained from
NOR-positive red blood cells (NOR+) and 2102Ep cells: untransfected
(NAT), transfected with vector encoding the consensus Gb3/CD77 syn-
thase (WT) and transfected with vectors encoding Gb3/CD77 synthase
with p. Q211E (p. Q211E), p. Q211D (p. Q211D) or p. Q211N (p.
Q211N) substitutions were detected by orcinol staining (orcinol) or by
overlaying with human anti-P1 antibody (human anti-P1 antibody, panels
3a and 3c), mouse anti-P1 antibody (mouse anti-P1 antibody, panel 3b)
and mouse anti-NOR antibody (anti-NOR antibody, panels 3a and 3c)
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glutamic acid (less favorable) at position 211. Since nei-
ther asparagine nor aspartic acid can replace these resi-
dues without abolishing the enzyme activity, it may be
speculated that none of the remaining proteinogenic ami-
no acids would allow preservation of its catalytic proper-
ties. In addition, since N and D differ from Q and E by
only one methylene group, respectively, our results sug-
gest that size of the 211 residue side chain is crucially
important for activity and apparently more important than
the type of functional group in the side chain. These ob-
servations raise the possibility that the amino acid residue
at position 211 of Gb3/CD77 synthase may be located
near the active center of the enzyme, which requires fur-
ther studies. Finally, since it seems that NOR antigens
represent a minor fraction of the Gb3/CD77 synthase
products (about 2.5 % of P1 specific binding capacity),
it may be argued that NOR-synthesizing pathway is a
small offshoot of enzyme activity.
When analyzing influence of amino acid replacement on
glycosyltransferase activity, one must take into consideration
that such change may affect intracellular localization of the
enzyme. However, in our opinion it is highly unlikely, because
glutamine, asparagine, glutamic acid and glutamine are very
similar amino acids, differing only by either amido group or
methylene group. Furthermore, 211 amino acid position of
Gb3/CD77 synthase is substantially distant from the predicted
transmembrane domain, which is the primary region contrib-
uting to subcellular localization of glycosyltransferases. In
addition, precise determination of intracellular localiza-
tion of the enzyme would require tagging (e.g. with
myc-tag or FLAG-tag), which may impede protein folding
and/or influence interaction with other proteins. Such
studies will be more feasible and less fallible once a spe-
cific anti-enzyme antibody is available.
Indisputably, substitution of one amino acid residue in the
glycosyltransferase can alter, broaden or abolish its activity
and consequently lead to changes in the synthesized blood
antigens. Several papers were published on changes in donor
specificity of different glycosyltransferases. The most thor-
oughly studied glycosyltransferases are GTA (α1,3-N-
Fig. 4 Flow cytometry quantification of specific antibody-binding ca-
pacity. Comparison of quantitative measurement of P1 and Pk antigens
(a) and NOR antigens (b) on the surface of untransfected 2102Ep cells
(NAT) and 2102Ep cells transfected with vectors encoding various forms
of Gb3/CD77 synthase: consensus Gb3/CD77 synthase (WT); Gb3/
CD77 synthase with E at position 211 (p. Q211E); Gb3/CD77 synthase
with D at position 211 (p. Q211D) and Gb3/CD77 synthase with N at
position 211 (p. Q211N)
Fig. 5 Quantitative analysis of A4GALT transcripts. NAT: untransfected
2102Ep cells;WT: consensus Gb3/CD77 synthase; p. Q211E: Gb3/CD77
synthase with E at position 211; p. Q211D: Gb3/CD77 synthase with D at
position 211; p. Q211N: Gb3/CD77 synthase with N at position 211
Fig. 6 Comparison of mean threshold cycle (CT) values between RNA
samples treated with reverse transcriptase (RT+) and untreated (RT-).
NAT: untransfected 2102Ep cells; WT: consensus Gb3/CD77 synthase;
p. Q211E: Gb3/CD77 synthase with E at position 211; p. Q211D: Gb3/
CD77 synthase with D at position 211; p. Q211N: Gb3/CD77 synthase
with N at position 211
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acetylgalactosaminyltransferase) and GTB (α1,3-
galactosyltransferase), the enzymes synthesizing ABO blood
group antigens. They catalyze the transfer of GalNAc or Gal,
respectively, from a UDP-sugar donor to Fucα1-2Galβ-R ac-
ceptor substrates. GTA and GTB are highly homologous en-
zymes, encoded by the same locus and differing at only four
positions of the 354-amino acid polypeptide [28]. It was
shown that a change of only one of these four residues renders
the mutant enzyme able to transfer either of the two sugar
residues, galactose and N-acetylgalactosamine, from UDP-
Gal and UDP-GalNAc, respectively, and leads to the cis-AB
phenotype [6]. Two amino acid residues, 266 and 268, are
critical for altering the specificity of transferases A and B.
Mutations c.796C > A (p. L266 M) and c.803G > C (p.
G268 A) cause enzyme to transfer galactose instead of N-
acetylgalactosamine [29]. GTB cannot bind UDP-GalNAc,
since the active site comprises amino acid residues with
longer side chains (266 M and 268 A), which restrict
access to a larger substrate. In the case of GTA, smaller
amino acid residues (268G and 266 L) allow the binding
of N-acetylgalactosamine [2]. It was recently shown that
the glycine residue present at position 266 in cis-AB
transferase allows both nucleotide sugars to enter the ac-
tive site of the enzyme [30].
Another example of how single amino acid residue can
modulate enzyme activity is β1,4-galactosyltransferase, an
enzyme that normally transfers Gal from UDP-Gal to
GlcNAc residue. Replacement of Y at position 289 to L, I or
N broadens the donor specificity, so mutated enzyme can use
both UDP-Gal and UDP-GalNAc as the donor [7].
α1,3/4-fucosyltransferases encoded by FUT3 (responsible
for synthesis of Lewis histo-blood group antigens) and FUT5,
are able to transfer fucose residues to the penultimate N-
acetylglucosamine of two different acceptors, called type 1
and type 2, while most of their closest counterparts (α1,3-
fucosyltransferases) employ only type 2 substrate. Both ac-
ceptors are terminated with galactose residue, but it is β1,4-
linked and β1,3-linked to N-acetylglucosamine in the case of
type 2 and type 1, respectively. Thus, the bispecificity is dic-
tated by structure of the two substrates (each presenting only
one free position for fucose attachment, 3 or 4, with the other
being already occupied by the terminal galactose), rather than
preference of the enzymes. However, the bispecificity de-
pends on only one amino acid residue: FUT3 and FUT5
fucosyltransferases contain W at position 111, which is occu-
pied by R in all monospecific α1,3-fucosyltransferases [31].
What still makes Gb3/CD77 synthase unique is that it can
transfer the same sugar not just to different acceptors that
differ en bloc, but in addition the glycosidic bond may be
formed with two different sugar residues (Gal and GalNAc)
that cap these acceptors, a phenomenon never described be-
fore in relation to a single point mutation [8]. In conclusion,
we show that a single amino acid change has a dramatic effect
on the specificity and activity of Gb3/CD77 synthase. We
confirm that replacement of Q with E at position 211 of
Gb3/CD77 synthase results in the formation of Pk, P1 and
NOR antigens and for the first time evaluate quantitatively
the ability of the enzyme to synthesize different products.
However, our data show that substitution of Q or E at this
position by similar amino acids causes a complete abolition
of the enzyme activity, which suggests that the amino acid 211
is crucially important for Gb3/CD77 synthase activity and
may be directly involved in the catalytic reaction. The struc-
ture and kinetics of the consensus and the p. Q211E form of
Gb3/CD77 synthase are currently under investigation.
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